Joseph Leach, MD
Medical Oncology · Maple Grove, MNNPI 1922083336
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,465 of the $6,201 with a category attached, or 88.1%. AstraZeneca accounts for 91.9% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $5,669 and has fallen 99.1% since, to $51 in 2025.
Across 14 payments — averaging $442.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- GSK$168
- Johnson & Johnson$118
- ASD Specialty Healthcare, LLC$111
- Merck$51
- Astellas Pharma Global Development$26
- plus $25 from 2 others
Across 23 payments — averaging $25,242 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$422K
- AstraZeneca$100K
- Geistlich Pharma, North America, Inc.$40K
- Biontech SE$14K
- Dynavax Technologies Corporation$3K
- Amgen$1K
- plus $50 from 1 others
What the payments were for
- Consulting fees$5,46588%
- Food & beverage$66011%
- Education$761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $5,702 |
| GSK | 1 | $168 |
| Johnson & Johnson | 1 | $118 |
| ASD Specialty Healthcare, LLC | 1 | $111 |
| Merck | 2 | $51 |
| Astellas Pharma Global Development | 1 | $26 |
| Novocure Inc. | 1 | $13 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,201 in reported general payments places this provider in the 65th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 47 | $790,173 |
| EliquisApixaban | 12 | $13,981 |
| Tamoxifen Citrate | 18 | $818 |
| Anastrozole | 17 | $393 |
| Letrozole | 15 | $345 |
| Prochlorperazine Maleate | 30 | $327 |
| Ondansetron Hcl | 16 | $213 |
| Dexamethasone | 11 | $196 |
| Prednisone | 17 | $135 |
| Olanzapine | 13 | $97 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $5,702 | $790,17347 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 133 medical oncology providers in Minnesota.
Other medical oncology in Maple Grove
- Amy KrieMinneapolis$907K
- Amit MahipalRochester$746K
- Alton SartorRochester$688K
- Ben GeorgeRochester$579K
- Noel LaudiCoon Rapids$274K
- Emmanuel AntonarakisMinneapolis$260K
- Elisabeth HeathRochester$236K
- Matthew GoetzRochester$136K
- Charles RyanMinneapolis$99K
- Dean GesmeMinneapolis$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.